Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) - Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).
2004 | conference abstract. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphomplasmocytoid/ic immumocytoma (LP-IC) - Results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG).
Buske, C.; Dreyling, M. H.; Eimermacher, H.; Boeck, H. P.; Pfreundschuh, M.; Metzner, B. & Fuchs, R. et al. (2004)
Blood, 104(11) 46th Annual Meeting of the American-Society-of-Hematology, San Diego, CA.
Washington: Amer Soc Hematology.
Documents & Media
Details
- Authors
- Buske, Christian; Dreyling, Martin H.; Eimermacher, Hartmut; Boeck, H. P.; Pfreundschuh, Michael; Metzner, Bernd; Fuchs, Rene; Woermann, Bernhard; Truemper, Lorenz H.; Hess, Georg; Wandt, Hannes; Ludwig, W. D.; Kreuser, E. D.; Schimke, J.; Weh, H. J.; Schmitz, S.; Schmiegel, W.; Unterhalt, Michael; Hiddemann, Wolfgang
- Issue Date
- 2004
- Status
- published
- Publisher
- Amer Soc Hematology
- Journal
- Blood
- Conference
- 46th Annual Meeting of the American-Society-of-Hematology
- Conference Place
- San Diego, CA
- ISSN
- 0006-4971
- Extent
- 50A
